tiprankstipranks
Trending News
More News >
Materialise NV (MTLS)
NASDAQ:MTLS
Advertisement

Materialise (MTLS) AI Stock Analysis

Compare
893 Followers

Top Page

MTLS

Materialise

(NASDAQ:MTLS)

Rating:66Neutral
Price Target:
$5.50
▲(3.58%Upside)
Materialise's overall stock score is influenced by strong financial performance and growth in the Medical segment, despite challenges in Manufacturing and Software. The technical indicators suggest potential bearish sentiment, but the company's strategic investments and partnerships provide a positive outlook. The valuation reflects growth prospects, though it comes at a premium.

Materialise (MTLS) vs. SPDR S&P 500 ETF (SPY)

Materialise Business Overview & Revenue Model

Company DescriptionMaterialise NV provides additive manufacturing and medical software, and 3D printing services in the Americas, Europe and Africa, and the Asia-Pacific. The company operates through three segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. Its Materialise Software segment offers software through programs and platforms that enable and enhance the functionality of 3D printers and of 3D printing operations. Its software interfaces between various types of 3D printers; and various software applications and capturing technologies, including computer-aided design/computer-aided manufacturing packages and 3D scanners. This segment serves 3D printing machine manufacturers; production companies and contract manufacturers in automotive, aerospace, consumer goods, and hearing aid industries; and 3D printing service bureaus through its sales force, Website, and third-party distributors. The company's Materialise Medical segment provides medical software that allows medical-image based analysis and engineering, as well as patient-specific design of surgical devices and implants. It serves medical device companies, hospitals, universities, research institutes, and industrial companies through its direct sales force, Website, and picture archiving and communication system partners. Its Materialise Manufacturing segment provides 3D printing services, design and engineering services, and rapid prototyping and additive manufacturing of production parts to industrial and commercial customers. The company has collaboration agreements with Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc. Materialise NV was incorporated in 1990 and is headquartered in Leuven, Belgium.
How the Company Makes MoneyMaterialise generates revenue through multiple streams, with a strong focus on its software and services. The company's 3D printing software solutions, which include licenses and subscriptions for its proprietary software platforms, are a significant source of income. Additionally, Materialise offers 3D printing services, catering to industries such as healthcare, automotive, and aerospace, where it provides customized manufacturing solutions. The healthcare segment is particularly important, with revenue coming from the development and production of patient-specific medical devices and implants. Materialise's strategic partnerships with major companies in various sectors also enhance its revenue potential, as these collaborations often lead to increased adoption of its software and services. Furthermore, Materialise continues to invest in research and development to expand its capabilities and maintain a competitive edge in the rapidly evolving 3D printing industry.

Materialise Earnings Call Summary

Earnings Call Date:Jul 24, 2025
(Q2-2025)
|
% Change Since: -14.08%|
Next Earnings Date:Oct 23, 2025
Earnings Call Sentiment Neutral
Materialise NV's earnings call highlighted strong performance and growth in the Medical segment, significant partnerships, and a solid financial position. However, these positives were countered by revenue declines in the Manufacturing and Software segments, impacted by geopolitical and macroeconomic challenges, leading to a revised revenue guidance.
Q2-2025 Updates
Positive Updates
Medical Segment Double-Digit Growth
Materialise Medical achieved high double-digit growth with revenue increasing by almost 17% this quarter, posting a quarterly revenue record.
Record Gross Profit Margin
Gross profit margin increased to 58.3% in the second quarter of 2025, reflecting changes in revenue mix and optimized direct production costs.
Pilot Collaboration with Johnson & Johnson
Announced a pilot collaboration with Johnson & Johnson's Surgical business in EMEA to advance the adoption of the Mimics thoracic planner.
U.S. Market Clearance for Personalized Knee Guides
Received 510(k) U.S. market clearance for personalized alignment feature in knee planner, allowing surgeons to tailor knee implant positioning.
Strong Balance Sheet and Positive Cash Flow
Generated a positive free cash flow leading to a net cash position of EUR 63 million at the end of Q2, an increase of EUR 2 million year-to-date.
Collaboration with Synera
Announced partnership with Synera to establish direct connectivity between Magics SDKs and Synera's AI platform for engineers, enhancing AM workflows.
Negative Updates
Revenue Decline
Total consolidated revenue decreased year-over-year by 5.8% to EUR 64.8 million, impacted by geopolitical and macroeconomic factors.
Manufacturing Segment Challenges
Manufacturing revenue declined by almost 25% due to geopolitical uncertainty and macroeconomic headwinds.
Software Segment Revenue Decline
Software revenue decreased by 12% due to macroeconomic uncertainty and unfavorable foreign exchange rates.
Foreign Exchange Impact
Net financial result for the quarter was negatively impacted by foreign exchange fluctuations amounting to a loss of EUR 3.3 million.
Revised Revenue Guidance
Slightly reduced full-year revenue guidance from EUR 270-285 million to EUR 265-280 million due to geopolitical and macroeconomic uncertainty.
Company Guidance
During the Materialise NV Second Quarter 2025 Financial Results Conference Call, the company provided guidance for the fiscal year 2025 with cautious optimism amid challenging macroeconomic conditions. The revenue guidance was slightly reduced from the previously communicated range of EUR 270 million to EUR 285 million to a range of EUR 265 million to EUR 280 million, reflecting risks associated with geopolitical volatility and foreign exchange fluctuations. However, the fundamentals of the company's business were described as solid and resilient, allowing Materialise to maintain its adjusted EBIT guidance between EUR 6 million and EUR 10 million, consistent with earlier forecasts. Despite these challenges, the company remains focused on safeguarding operational profitability through structural cost efficiencies and strategic investments, particularly in its growing Medical segment, which achieved a notable 17% revenue increase this quarter.

Materialise Financial Statement Overview

Summary
Materialise shows consistent revenue growth with strong gross profit margins. However, operational efficiency pressures are indicated by decreased EBIT margins. The balance sheet is healthy with low leverage, but liquidity constraints are noted. Stable cash flow generation, despite volatility in free cash flow, highlights a solid financial position.
Income Statement
75
Positive
Materialise has shown a consistent growth trajectory in total revenue over the years, with a notable increase from $170.4M in 2020 to $269.9M in TTM 2025. The gross profit margin remains strong at 56.3% in TTM, and the net profit margin has improved to 3.6% from negative levels in 2022. However, EBIT margin has decreased to 2.3% in TTM, indicating pressures on operational efficiency. EBITDA margin is solid at 11.8%, showing stable earnings before non-cash expenses.
Balance Sheet
70
Positive
The company maintains a healthy balance sheet with a debt-to-equity ratio of 0.15, suggesting a conservative leverage approach. The equity ratio stands at 63.7% in TTM, indicating strong equity financing. Return on Equity has improved to 3.9% in TTM, reflecting better profitability. However, the decrease in cash and short-term investments over the years indicates potential liquidity constraints.
Cash Flow
68
Positive
Operating cash flow to net income ratio is robust at 3.2 in TTM, highlighting strong cash generation relative to net income. However, free cash flow growth has been volatile, with TTM free cash flow at $5.8M, a slight improvement from previous periods. The free cash flow to net income ratio is lower at 0.6, indicating less cash available for expansion or dividends.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue269.86M266.76M256.13M232.02M205.45M170.45M
Gross Profit151.81M150.82M145.13M128.76M117.28M94.00M
EBITDA31.88M31.24M30.09M23.44M36.72M13.75M
Net Income9.58M13.44M6.72M-2.15M13.15M-7.27M
Balance Sheet
Total Assets390.45M396.34M396.63M411.26M413.41M327.67M
Cash, Cash Equivalents and Short-Term Investments104.18M102.30M127.57M140.87M196.03M111.54M
Total Debt36.44M41.28M64.40M80.98M99.11M115.11M
Total Liabilities141.75M147.84M160.04M182.33M180.83M194.56M
Stockholders Equity248.79M248.58M236.65M228.96M232.58M133.10M
Cash Flow
Free Cash Flow5.76M5.08M8.40M-64.00K14.12M12.33M
Operating Cash Flow30.78M31.46M20.16M24.71M25.84M29.98M
Investing Cash Flow-27.78M-28.59M-11.04M-53.92M-13.13M-28.27M
Financing Cash Flow-27.03M-27.64M-22.37M-24.87M71.16M-16.89M

Materialise Technical Analysis

Technical Analysis Sentiment
Negative
Last Price5.31
Price Trends
50DMA
5.57
Negative
100DMA
5.26
Positive
200DMA
6.19
Negative
Market Momentum
MACD
<0.01
Positive
RSI
40.30
Neutral
STOCH
10.43
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTLS, the sentiment is Negative. The current price of 5.31 is below the 20-day moving average (MA) of 5.75, below the 50-day MA of 5.57, and below the 200-day MA of 6.19, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 40.30 is Neutral, neither overbought nor oversold. The STOCH value of 10.43 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MTLS.

Materialise Risk Analysis

Materialise disclosed 72 risk factors in its most recent earnings report. Materialise reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Materialise Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
$332.63M54.8214.17%0.39%9.73%22.33%
67
Neutral
$346.12M1.92-10.56%2.13%-11.07%953.01%
66
Neutral
$313.65M51.252.21%3.63%-48.48%
66
Neutral
$368.43M-5.62%-3.34%56.44%
64
Neutral
$410.90M-64.59%5.33%58.41%
63
Neutral
$34.93B5.92-11.89%1.97%5.61%-19.51%
48
Neutral
$305.71M-104.69%-1.64%9.99%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MTLS
Materialise
5.31
-1.19
-18.31%
TRAK
ReposiTrak
17.61
-1.43
-7.51%
API
Agora
3.82
1.32
52.80%
BIGC
BigCommerce Holdings
4.93
-3.17
-39.14%
MKTW
MarketWise
20.76
0.46
2.27%
NRDY
Nerdy
1.58
-0.15
-8.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 25, 2025